Telomere dysfunction is implicated in the generation of large-scale genomic rearrangements that drive progression to malignancy. In this study we used high-resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) and 95 de novo acute myeloid leukaemia (AML) patients. Despite the MDS cohort being older, they had significantly longer telomeres than the AML cohort (P < 0Á0001) where telomere length was also significantly shorter in younger AML patients (age <60 years) (P = 0Á02) and in FLT3 internal tandem duplication-mutated AML patients (P = 0Á03). Using a previously determined telomere length threshold for telomere dysfunction (3Á81 kb) did not provide prognostic resolution in AML [Hazard ratio (HR) = 0Á68, P = 0Á2]. In contrast, the same length threshold was highly prognostic for overall survival in the MDS cohort (HR = 5Á0, P < 0Á0001). Furthermore, this telomere length threshold was an independent parameter in multivariate analysis when adjusted for age, gender, cytogenetic risk group, number of cytopenias and International Prognostic Scoring System (IPSS) score (HR = 2Á27, P < 0Á0001). Therefore, telomere length should be assessed in a larger prospective study to confirm its prognostic role in MDS with a view to integrating this variable into a revised IPSS.
Summary
Telomere dysfunction is implicated in the generation of large-scale genomic rearrangements that drive progression to malignancy. In this study we used high-resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) and 95 de novo acute myeloid leukaemia (AML) patients. Despite the MDS cohort being older, they had significantly longer telomeres than the AML cohort (P < 0Á0001) where telomere length was also significantly shorter in younger AML patients (age <60 years) (P = 0Á02) and in FLT3 internal tandem duplication-mutated AML patients (P = 0Á03). Using a previously determined telomere length threshold for telomere dysfunction (3Á81 kb) did not provide prognostic resolution in AML [Hazard ratio (HR) = 0Á68, P = 0Á2]. In contrast, the same length threshold was highly prognostic for overall survival in the MDS cohort (HR = 5Á0, P < 0Á0001). Furthermore, this telomere length threshold was an independent parameter in multivariate analysis when adjusted for age, gender, cytogenetic risk group, number of cytopenias and International Prognostic Scoring System (IPSS) score (HR = 2Á27, P < 0Á0001). Therefore, telomere length should be assessed in a larger prospective study to confirm its prognostic role in MDS with a view to integrating this variable into a revised IPSS.
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The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic disorders with varying survival and propensity to develop secondary acute myeloid leukaemia (sAML). The initial International Prognostic Scoring System (IPSS) for MDS was based on the bone marrow blast count, 3 distinct cytogenetic risk groups and the number of cytopenias, dividing patients into four IPSS subgroups (Greenberg et al, 1997) . The revised IPSS (IPSS-R) is an updated refinement of the IPSS, which identifies five cytogenetic, three cytopenic and four blast count risk categories that combine into five overall prognostic subgroups (Vardiman et al, 2009; Greenberg et al, 2012) . Many MDS patients have a normal karyotype but in recent years a very large number (up to 660) of molecular genetic defects have been identified in genes that encode cellular proteins, including transcription factors e.g. RUNX1, epigenetic regulators and chromatin remodelling factors e.g. TET2, DNMT3A, IDH1/2, pre-RNA splicing factors e.g. SF3B1, receptor tyrosine kinase/ signalling molecules e.g. NRAS, JAK2, NPM1, FLT3 and the check point regulator TP53, some of which impact significantly on prognosis (Walter et al, 2012; Tothova et al, 2013) . A recent MDS study showed that some of these somatic mutations were independent prognostic markers compared to the IPSS (Bejar et al, 2011) .
Recent studies have shown that the same genomic mutations seen in MDS/AML patients overlap with those identifiable in the normal adult population that show increasing frequency with age (Genovese et al, 2014; Jaiswal et al, 2014; Xie et al, 2014; . What drives these clones to further genomic instability and the development of MDS/AML is currently poorly understood. Telomeres are repetitive DNA sequences at the ends of chromosomes that shorten with each cell division. Critical loss of telomere length leads to chromosome end-end fusion and genomic instability, resulting in large scale re-arrangements, such as non-reciprocal translocations, which are the hallmark of many tumour types including MDS, sAML and de novo AML . With ongoing cell division during life, the telomeres in normal individuals erode as a function of age at a rate of approximately 26 bp/year (Daniali et al, 2013) . Several studies have suggested that MDS is associated with shorter telomeres, leading to genomic instability and progression to sAML (Boultwood et al, 1997; Sieglova et al, 2004; Chakraborty et al, 2009; Young, 2010; Townsley et al, 2014) . Recently, using a modified quantitative fluorescence in situ hybridization (Q-FISH)-based method, Gadji et al (2012) proposed that telomere dysfunction underpins the chromosomal changes associated with MDS progression to AML and de novo AML. In a mouse model it was shown that telomere dysfunction induced the same types of DNA damage that drives classical MDS phenotypes, including SF3B1 and DNMT3A, resulting in differentiation changes in myeloid precursors (Colla et al, 2015) .
We previously developed a high-resolution technique to determine telomere length, Single Telomere Length Analysis (STELA), which is unique in its ability to detect telomere lengths from single chromosomes within the length ranges at which telomere fusions can occur (Lin et al, 2010 (Lin et al, , 2014 . Using STELA we have shown that some chronic lymphocytic leukaemia (CLL) patients display extreme telomere shortening and fusion, consistent with the onset of a telomere-driven crisis that can drive the formation of large-scale genome rearrangements (Lin et al, 2010) . Telomeres in these ranges cannot be readily detected with the other methodologies, such as quantitative polymerase chain reaction (QPCR), Southern blot or Q-FISH previously used in MDS/AML studies (Baird et al, 2003; Chakraborty et al, 2009; Lin et al, 2010; Britt-Compton et al, 2012) . We showed that in CLL patients, telomere fusions only occurred when telomere length was ≤3Á81 kb and, importantly, we show that telomere erosion to within these length ranges precedes clinical progression. Indeed, high-resolution telomere length analysis using STELA, together with the stratification of patients based on the telomere length thresholds at which fusion occurs, provided an independent high-resolution marker of prognosis even in patients with early-stage CLL (Lin et al, 2014) .
In this study we used STELA to assess if telomere erosion is an important pathogenic mechanism driving prognosis MDS and AML.
Methods
Patients, samples and cell separation (Table I) . We deliberately chose to use stored but well annotated archival samples so as to be able to assess the potential impact of telomere length on survival in all patient groups, especially low risk MDS patients. All MDS patients were treated with best supportive care with none receiving azacitidine prior to this analysis. All morphological, immunophenotypic, cytogenetic and molecular data were collected from Cardiff and Dundee Haematology Departments for their respective patients but all telomere length analyses on the bone marrow mononuclear cells were undertaken within the Division of Cancer and Genetics, Cardiff University. Bone marrow mononuclear cells were collected in ethylenediaminetetraacetic acid (EDTA) and isolated by density centrifugation using Ficoll-Hypaque (Invitrogen, Thermo Scientific, Waltham, MA, USA) which resulted in <3% lymphocytes contamination. Cells were stored at À20°C as dry pellets before DNA extraction.
DNA extraction, single telomere length analysis and telomerase assays
Telomere length was determined using XpYp STELA as previously described (Lin et al, 2010; Roger et al, 2013) . Briefly, DNA was extracted using proteinase K, RNase A, phenol/chloroform protocols and quantified by Hoechst 33258 fluorometry (Bio-Rad, Hercules, CA, USA) before dilution to 10 ng/ll in 10 mmol/l Tris-HCl, pH 7Á5. A total of 10 ng of DNA was further diluted to 250 pg/ll in a volume of 40 ll containing 1 lmol/l Telorette2 linker and 1 mmol/l Tris-HCl, pH 7Á5. Multiple polymerase chain reactions (PCRs; typically 6 reactions per sample) were carried out for each test DNA in 10-ll volumes with 250 pg of DNA, 0Á5 lmol/l of the telomere-adjacent and Teltail primers, 75 mmol/l Tris-HCl, pH 8Á8, 20 mmol/l (NH 4 ) 2 SO 4 , 0Á01% Tween-20, 1Á5 mmol/l MgCl 2 , and 0Á5 units of a 10:1 mixture of Taq (ABGene, Thermo Scientific) and Pwo polymerase (Roche Molecular Biochemicals, Burgess Hill, West Sussex, UK). The reactions were cycled with an MJ PTC-225 thermocycler (MJ Research, Bio-Rad). The DNA fragments were resolved by 0Á5% Tris acetate EDTA agarose gel electrophoresis, and detected by Southern blot hybridization with random-primed a-33 P-labelled (GE Healthcare, Chicago, IL, USA) TTAGGG repeat probe together with probes to detect the 1-kb (Stratagene, Agilent Technologies, Santa Clara, CA, USA) and 2Á5-kb (Bio-Rad) molecular weight markers. The hybridized fragments were detected by phosphorimaging with a Molecular Dynamics Storm 860 phosphorimager (GE Healthcare). The molecular weights of the DNA fragments were calculated using the Phoretix 1D quantifier (Nonlinear Dynamics, Newcastle upon Tyne, UK). Telomerase assays were undertaken using the TRAPeze XL Telomerase detection kit (Chemicon International, Billerica, MA, USA) as previously described (Lin et al, 2010; Roger et al, 2013) . 
Statistical methods
Statistical analysis was undertaken by the Haematology Clinical Trials Unit, Cardiff University using SAS version 9.4 (SAS Institute, Cary, NC) and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA). Spearman's correlation was used for correlations between baseline values; Mann-Whitney and Wilcoxon matched-paired nonparametric tests were used for comparisons between groups. Mean telomere length was assessed between diagnoses using the Wilcoxon rank sum test. Paired data were compared using the Wilcoxon signed rank test. Patients in the MDS cohort were assessed using the 1997 IPSS criteria (Greenberg et al, 1997) for the 3 cytogenetic risk groups, blast count, number of cytopenias (Hb <100 g/l, neutrophil count <1Á5 9 10 9 /l and platelet count <100 9 10 9 /l), IPSS score, age and sex, whereas the AML cohort was assessed for cytogenetic risk group and FLT3 and NPM1 mutations (Kottaridis et al, 2001; Falini et al, 2005; Townsley et al, 2014) . Survival was assessed using the Kaplan-Meier method, and compared using Cox proportional hazards regression, with model building carried out using forward selection with significance set at P = 0Á05.
Results

Telomere length MDS and AML patients
An MDS patient's bone marrow will typically display a variable range of immature and more differentiated cells that may or may not be derived from the malignant stem cells. We therefore compared the telomere length of the first 20 individual MDS patients CD34 + and CD34 À bone marrow cells, but found no significant difference in telomere length between the two fractions (P = 0Á08; Figure S1A ). We therefore proceeded without cell selection in subsequent MDS patient bone marrow sample analyses and simply used bone marrow mononuclear cell pellets. Despite the fact that the MDS patients (median age 68 years, range 21-86 years) were older than AML patients (median age 56 years, range 17-80 years) telomere length was significantly longer in the MDS cohort compared to the AML cohort (P < 0Á0001; Fig 1A) . Although MDS samples showed a modest reduction in telomere length with increasing age at diagnosis, there was no significant correlation (q 2 = À0Á0212, P = 0Á2; Fig 1B) whereas in the AML samples a positive correlation was observed (q 2 = 0Á0890, P = 0Á003; Fig 1C) . This finding is in contrast to what occurs during normal ageing; samples derived from older AML patients (age >60 years) had significantly longer telomeres than younger AML patients (P = 0Á02; Fig 1D) . Indeed, 22/ 26 (84Á6%) of AML patients aged <50 years had telomere lengths within the range at which they can become dysfunctional or 'fusogenic' (≤3Á81 kb), which we previously described in CLL (Lin et al, 2014) . Telomere length, blast count, cytogenetics, cytopenias and IPSS
We next analysed the MDS cohort to assess any possible correlations between telomere length and age, gender, blast count, number of cytopenias, cytogenetic risk group and IPSS sub-group. Shorter telomere length was associated with male gender (P = 0Á01; Figure S1B ) and increased number of cytopenias (P = 0Á003; Fig 2A) . None of the other parameters were significantly associated with telomere length. Consistent with previous reports (Greenberg et al, 1997 (Greenberg et al, , 2012 we found a significant association between the number of cytopenias and overall survival (P < 0Á0001; Figure S2A ). Furthermore, patients with high-risk cytogenetic abnormalities tended to have worse survival although this did not reach statistical significance (P = 0Á12; Figure S2B ).
Interestingly we found no simple association between telomere length and the three IPSS cytogenetic risk groups (P = 0Á6 for trend; Fig 2B) , the four IPSS subgroups (q 2 = 0Á14 for correlation; Fig 2C) or bone marrow blast percentage (q 2 = À0Á22, P = 0Á0503 Fig 2D) .
In the de novo AML cohort we assessed the correlation between telomere length and gender, age, presenting white blood cell (WBC) count, performance status, whether primary or secondary AML and NPM1 and FLT3 mutation status. There was no association between NPM1-mutated patients and telomere length (data not shown), but significantly shorter telomeres were found in the FLT3 internal tandem duplication (ITD)-mutated group when compared to FLT3 wild type AML patients (P = 0Á03). In contrast, there was a trend towards longer telomeres in the FLT3 tyrosine Fig 1. (A) Telomere length in the MDS cohort was significantly longer than those of the AML cohort despite being older; median age 68 vs. 56 years (P < 0Á0001). (B) In MDS patients there was no correlation between telomere length and age of diagnosis (q 2 = 0Á0212; P = 0Á2). (C) In AML patients there was a positive correlation between telomere length and age of diagnosis (q 2 = 0Á0890; P = 0Á003). (D) Older AML patients (age >60 years) had significantly longer telomeres than younger patients (P = 0Á02). AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; SD, standard deviation. 
Telomerase activity in MDS and AML patients
Given the different telomere length characteristics of the MDS and AML cohorts, we investigated whether this may reflect differences in telomerase activity, an enzyme responsible for extending shortened telomeres. Telomerase activity was analysed in a subset of CD34 + AML samples (n = 12) and in purified CD34 + cells from MDS patients (n = 20).
Telomerase activity was significantly higher in the AML samples when compared with CD34 + MDS cells (P = 0Á0002; Fig 2F) .
Telomere length and survival in MDS and AML
We next assessed the impact of telomere length on overall survival in the MDS and AML cohorts. Segregation of the two cohorts according to whether their mean telomere length was above or below the upper limit of telomere dysfunction (3Á81 kb) revealed no difference in survival in the AML patient group [Hazard ratio (HR) = 0Á68 (95% confidence interval (CI), 0Á37-1Á9), P = 0Á2; Fig 3A] . In contrast, bifurcation of the MDS cohort using this threshold telomere length demonstrated that patients with a median telomere length ≤3Á81 kb had significantly worse survival [HR = 5Á0 (95% CI, 2Á7-10Á0), P < 0Á0001; Fig 3B] . The impact of telomere length in these two disease settings was confirmed using telomere length quartile analysis. There was no correlation between telomere length and overall survival or relapse-free survival in the AML cohort (P = 0Á5, P = 0Á09; Figure S3A and B). However, similar quartile analysis in the MDS cohort clearly showed that patients in the lowest two quartiles had worse survival, with all patients in the lowest quartile alive at 3 years ( Figure S3C ).
Telomere length is an independent prognostic variable in MDS
Finally, we performed multivariate analysis in the MDS cohort using a forward selection model that included age, IPSS, gender, cytogenetic risk group, number of cytopenias and telomere length. Short telomere length was identified as the most significant independent marker of overall survival (HR = 2Á27 (95% CI, 1Á45-3Á57), P < 0Á0001 
Discussion
We previously showed that a proportion of CLL patients display extreme telomere erosion and fusion consistent with a telomere-driven crisis (Lin et al, 2010) . Importantly, this was not simply a function of advanced stage disease but was detected in a subset of early stage patients prior to clinical progression (Lin et al, 2010 ). Subsequently we showed that defining the specific telomere length threshold at which telomere fusion occurred was a powerful way to risk-stratify CLL patients, even those with early-stage disease (Lin et al, 2014) . Previous studies had suggested a possible role for telomere dysfunction in both MDS and AML (Boultwood et al, 1997; Ohyashiki et al, 1999; Sieglova et al, 2004; Chakraborty et al, 2009; Gadji et al, 2012) , so here we investigated the relationship between telomere length, disease progression and clinical outcome in MDS and AML using the high-resolution STELA technique. We demonstrated that telomere length was highly predictive of disease outcome in MDS. In contrast, we found no evidence that telomere length influenced the survival of de novo AML patients. It should be noted, however, that we demonstrated shorter telomere lengths in the FLT3-ITD mutated group, a group with a well-established poorer prognosis. These results are similar to those of Aalbers et al (2013) who also showed shorter telomeres in patients with FLT3-ITD mutations but not NPM1 mutated patients. One possible explanation for the different telomere length characteristics in MDS and AML may be the differential expression of telomerase found in these two conditions. Unlike MDS cells, AML cells showed evidence of upregulated telomerase activity, which could prevent replicative senescence and allow unlimited proliferation during leukaemogenesis (Engelhardt et al, 2004; Shay & Wright, 2011) . MDS is characterised by clonal expansion and hypercellularity but increased apoptosis, leading to cytopenias (Greenberg, 1998 (Greenberg, , 1999 Parker et al, 1998; Parker & Mufti, 2000) . The reason why telomerase is not upregulated in MDS is unknown, but studies to date have failed to show any responsible acquired telomerase-regulated genetic abnormalities in this patient group, although there are several germline mutations described in TERC and TERT predisposing to MDS/AML (Ohyashiki et al, 1999; Yamaguchi et al, 2003; Calado et al, 2009; Kirwan et al, 2009; Ballew & Savage, 2013) .
Our study showed an association between telomere length and the number of cytopenias in MDS patients. It seems possible that the lack of telomerase activity observed in MDS leads to unhindered cell senescence and/or apoptosis. Also, the high proliferative and apoptotic rates seen in MDS bone marrow produce increased ineffective haematopoiesis and more profound cytopenias (Raza et al, 1997a,b) . These results are similar to those of Sieglova et al (2004) who showed MDS patients with shorter telomeres were more likely to progress to AML. Perhaps surprisingly, there was no association between telomere length and cytogenetic risk group, blast count and IPSS score. This lack of association meant that telomere length was an independent marker of outcome in MDS and in the multivariate forward selection model we employed. Indeed, it was more prognostic than blast count, cytogenetics, number of cytopenias or IPSS in this context.
Several recent studies have shown that clonal haematopoiesis is almost a "normal" part of ageing, with recent reports showing 0Á8%, 11% and 19Á5% of normal individuals aged <60, >80 and >90 years respectively having demonstrable clonal haematopoiesis -so called age-related clonal haematopoiesis (Xie et al, 2014; . These include the acquisition of many genetic lesions associated with the development of MDS/AML, including DNMT3, IDH1, IDH2, NRAS, KRAS, JAK2, SF3B1 and SRSF2 mutations (Jaiswal et al, 2014; Xie et al, 2014; . Three of our observations in this study were that (i) the telomere length increases with age in AML patients, (ii) AML patients older than 60 years have significantly longer telomeres than those aged <60 years, and (iii) the AML patient cohort had significantly shorter telomeres than the MDS patient cohort despite being younger. One possible explanation for these data is that older de novo AML patients may have developed sAML despite the absence of a documented history of prior MDS or clonal haematopoiesis. This would be in keeping with the recent identification of increased genomic instability in ageing "normal" people with many identical genomic abnormalities seen in elderly AML patients . The acquisition of the various differing leukaemia-associated genomic abnormalities are age-dependent with, for example, the recurrent point mutations affecting spliceosome genes SF3B1 and SRSF2 associated with clonal haematopoiesis in individuals aged 70 years or over, but not in younger people (Papaemmanuil et al, 2013; . An alternative, but not exclusive hypothesis, is that AML in younger patients tends be more progenitor-type AML (Core binding factor, NPM1-mutated, FLT3-ITD-mutated) and more proliferative, leading to shorter telomeres. Further studies are required to assess the relationship of shorter telomeres with age-related clonal haematopoiesis and MDS and AML development.
The findings in MDS are in keeping with our previous data in CLL and breast cancer where we demonstrated the utility of our telomere-length threshold in providing powerful independent prognostic information (Roger et al, 2013; Lin et al, 2014) . Taken together, these data point to a common mechanism that is present in diverse tumour types, by which the presence of short dysfunctional telomeres can drive genomic instability and clonal evolution, leading to poor clinical outcomes.
Our study does have several limitations in that it consists of relatively small cohorts of MDS and AML patients and was deliberately retrospective so as to be able to assess the impact of telomere length on survival, especially in low risk MDS patients, all of who were treated with supportive care only. Finally, our observation that telomere length is independently prognostic in MDS indicates that consideration Fig 3. (A) Using our previously described chronic lymphocytic leukaemia fusogenic length threshold (telomere length ≤3Á81 kb) there is no difference in survival in AML patients [HR = 1Á47 (95% confidence interval (CI), 0Á80-2Á68], P = 0Á2. (B) In contrast, categorization of the MDS cohort above and below the fusogenic length threshold (3Á81 kb) demonstrated that MDS patients with short telomeres had an inferior survival (HR = 5Á0 (95% CI, 2Á7-10Á0), P < 0Á0001). AML, acute myeloid leukaemia; HR, hazard ratio; MDS, myelodysplastic syndrome.
should be given to a much larger prospective study assessing the potential role of telomeres in the prognostication of MDS. This would also facilitate the assessment of telomere length analysis as a potential predictor of response to newer therapies, such as azacitidine, and perhaps its ultimate incorporation into a revised IPSS.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . (A) In 20 MDS patients bone marrow mononuclear cells were sorted but there was no significant difference in telomere length in CD34 + and CD34 À selected sub-populations. (B) In the MDS cohort longer telomere length was associated with female sex (P = 0Á01). Figure S2 . (A) In the MDS cohort there was a significant association between the number of cytopenias and overall survival (P < 0Á0001). (B) In the MDS cohort patients with high risk cytogenetic lesions tended to have worse survival although this did not reach statistical significance probably due to the relatively small sample size (P = 0Á12). Figure S3 . Quartile analysis of telomere length revealed no significant difference in (A) overall survival and (B) relapsefree survival in the de novo AML cohort. In contrast, (C) MDS patients in the lower two telomere length quartiles showed significantly shorter overall survival.
